{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:31:14Z","timestamp":1773883874725,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jdcr.2023.06.051","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T02:30:48Z","timestamp":1690338648000},"page":"150-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)"],"prefix":"10.1016","volume":"39","author":[{"given":"Lisa","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-wan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2023.06.051_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"issue":"4","key":"10.1016\/j.jdcr.2023.06.051_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/archdermatol.2010.34","article-title":"Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: Results from a phase 2A, randomized, placebo-controlled clinical trial","volume":"146","author":"Bissonnette","year":"2010","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.06.051_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jdcr.2023.06.051_bib4","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1468-3083.2011.04332.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial","volume":"26","author":"Bissonnette","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"10.1016\/j.jdcr.2023.06.051_bib5","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1097\/CM9.0000000000001221","article-title":"A double-blind, randomized, placebo-and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"24","key":"10.1016\/j.jdcr.2023.06.051_bib6","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jdcr.2023.06.051_bib7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.06.051_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial","volume":"87","author":"Strober","year":"2022","journal-title":"J. Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jdcr.2023.06.051_bib9","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.jid.2022.05.1011","article-title":"LB987 Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in\u00a0vitro","volume":"142","author":"Mooney","year":"2022","journal-title":"JID"},{"issue":"1","key":"10.1016\/j.jdcr.2023.06.051_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1900027","article-title":"The role of memory CD8+ T cells in vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262300262X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262300262X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:21Z","timestamp":1762475121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251262300262X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":10,"alternative-id":["S235251262300262X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.06.051","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.06.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}